According to the WHO classification acute myeloid leukemia (AML) is categorized according to cytogenetic and molecular changes [1] . The subgroups with adverse, intermediate and favorable genetics were redefined and incorporated into the major factors predicting treatment-related mortality. Postremission therapy strategies are basically related to cytogenetic abnormalities; therefore for patients with favorable-risk AML repetitive cycles of high-dose cytarabine are considered superior to autologous or allogenic hematopoietic stem cell transplantation (auto-or allo-HSCT) [2, 3] .
The AML rarely may present in extramedullary form as a primary disease called myeloid sarcoma or as extramedullary relapse (EMR). In recent studies, EMR incidence following allo-HSCT is estimated to be from 5% to 11% and occurs in "sanctuary" sites, e.g. central nervous system, ovary and testis, as well as other anatomical locations including skin, muscle, body cavities, mammary glands, gastrointestinal tract and urinary tract [4] [5] [6] [7] . Up to 2010 as many as 163 cases of AML breast relapse were described but only 36% had karyotype evaluation [8] . We present two patients with AML favorable cytogenetics -inv(16)(p13;q22); CBFB (core binding factor β-chain)-MYH11 (myosin heavy chain 11 gene) -and EMR in breast after allo-HSCT. Case 1. AML M2 according to the French-American-British (FAB) classification with inv(16)(p13;q22) and without FLT3(Fms-like tyrosine kinase 3)-ITD(internal-tandem duplications) mutation was diagnosed in a 33-year-old female (Table I) /day, days -6 to -2) and anti-thymocyte globulin (ATG) at a total dose of 15 mg/kg, days -3 to -1. Then she received 10 × 10 6 CD34+ PBSC/ kg. For GvHD prophylaxis the same treatment was , days 1-5). Consolidation according to the HAM and HD-AraC regimens was performed with haematological, cytogenetic and molecular CR achievement. Subsequently, 8 cycles of maintenance chemotherapy were administered. As the first relapse occurred, the patient was given DAF reinduction followed with HAM consolidation, which initiated the next CR. Allo-HSCT from an HLA-identical unrelated donor was per- /l on day +17). Acute GvHD (skin -grade III, gastrointestinal tract -grade II according to the Glucksberg clinical classification [9] ) was diagnosed on day +9. Additional immunosuppressive treatment with steroid (methylprednisolone) was applied at a dose of 2.5 mg/kg a day and was slowly tapered with complete withdrawal on day +42 following allo-HSCT. Nevertheless, isolated mucosal chronic GvHD persisted. The patient remained in hematological, cytogenetic and molecular CR with 100% donor chimerism tested with the STR-PCR method after allo-HSCT. The EMR concerning entirely both breasts and bone marrow was reported at 48 and 10 months after the initial diagnosis and allo-HSCT respectively. /l on day +55). The immunosuppressive therapy was stopped on day +34 following the second allo-HSCT without signs of GvHD. The last relapse was observed at 51 months after the initial diagnosis and 5 months following the second allo-HSCT. This patient died one month later due to septic shock. The results of retrospective direct sequencing of exons 8 and 17 of c-KIT gene mutations in bone marrow sampled at the time of diagnosis and breast relapse tissue were both negative.
In studies to date on EMR after allo-HSCT, several risk factors have been taken into consideration, E but their comprehensive significance remains unclear. Several factors are thought to be associated with higher incidence of EMR including younger age of patients, extramedullary involvement prior to allo-HSCT, advanced AML, and unfavorable karyotype [10] [11] [12] [13] . Moreover, previous GvHD seems to occur more frequently in EMR compared with bone marrow relapse [6, 14] . The latest meta-analysis of AML extramedullary relapses in the breast, reported by Cunningham [8] In the current literature review no molecular markers characteristic for extramedullary relapses were specified. Such investigations were not performed in a group of good prognosis CBF AML patients with extramedullary breast relapses. Although CBF AML compared with other types of AML showed favorable prognosis, almost 50% had early relapse presentation and significant differences in overall survival [15, 16] . The presence of FLT3-ITD or c-KIT mutations was found to be associated with poor prognosis compared to wildtype patients [17] . Both of our patients were negative for FLT3-ITD and frequent c-KIT mutations but the prognosis after breast EMR differed: the first maintained bone marrow and breast CR (15 and 11 months) after consolidation and radiotherapy; the second one died 6 months after chemotherapy, radiotherapy and second allo-HSCT.
In conclusion, we present 2 patients with CBF AML and development of extramedullary breast relapse after allo-HSCT. Despite similar presentation and molecular marker expression, discrepancies in follow-up were observed. The absence of FLT3-ITD transcript and frequent c-KIT mutations may exclude the use of these adverse molecular markers in extramedullary breast relapses, but to confirm this correlation molecular research on a larger group of CBF AML patients with isolated extramedullary breast relapses is required.
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